Ann Oncol

1. CHEN X, Qiu MY, Zhang JP, Xia YD, et al
   Colorectal cancer detection using non-contrast CT and deep learning: a multicenter and international cohort study.
   Ann Oncol. 2026 Apr 21:S0923-7534(26)00150-X. doi: 10.1016/j.annonc.2026.
   

   >> Share

   
   

   
   Ann Surg Oncol

2. RADEMAKER E, Aktas BC, van den Berg R, Dekker JWT, et al
   The Impact of Postoperative Complications After Colon Cancer Surgery on Locoregional Recurrence: A Population-Based Dutch Cohort Study.
   Ann Surg Oncol. 2026 Apr 22. doi: 10.1245/s10434-026-19637.
   

   >> Share

   
   
3. TURRI G, Pedrazzani C, Ruben S, Barresi V, et al
   The Prognostic Role of Postoperative Inflammation After Minimally Invasive Resection for Colorectal Cancer.
   Ann Surg Oncol. 2026 Apr 19. doi: 10.1245/s10434-026-19673.
   

   >> Share

   
   
4. SMITH HG, Henriksen TV, Andersen CL
   ASO Author Reflections: Potential of Circulating Tumor DNA in Stratifying Patients with Localized pMMR Colon Cancer to Neoadjuvant Therapy.
   Ann Surg Oncol. 2026 Apr 19. doi: 10.1245/s10434-026-19682.
   

   >> Share

   
   

   
   BMC Gastroenterol

5. LIU L, Zhou L, Zhang H, He Y, et al
   Immune checkpoint inhibitor resistance in dMMR high-grade intraepithelial neoplasia with lynch syndrome-associated colon cancer: a case report.
   BMC Gastroenterol. 2026 Apr 23. doi: 10.1186/s12876-026-04816.
   

   >> Share

   
   
6. ZENG M, Lu H, Hong J, Liu R, et al
   Influencing factors of chemotherapy-induced peripheral neuropathy in colorectal cancer: a systematic review and meta-analysis.
   BMC Gastroenterol. 2026 Apr 20. doi: 10.1186/s12876-026-04833.
   

   >> Share

   
   

   
   BMJ Oncol

7. CHEN CY, Lee O
   CXCR4 in colorectal cancer: from prognostic marker to immunotherapy guide?
   BMJ Oncol. 2026;5:e001129.
   

   >> Share

   
   

   
   Cancer

8. OBA S, Okuno K, Watanabe S, Yamamoto Y, et al
   Intratumoral fungal burden of Candida tropicalis as a novel prognostic biomarker for recurrence and mortality in colorectal cancer.
   Cancer. 2026;132:e70408.
   

   >> Share

   
   

   
   Cancer Lett

9. ZOU H, Guo Y, Pan Q, Chen Y, et al
   New insights into the ambivalent role and clinical implications of tripartite motif family proteins in colorectal cancer.
   Cancer Lett. 2026;650:218514.
   

   >> Share

   
   
10. CHEN R, Rajasekaran S, Xing X, Zhang Q, et al
    Coordinated post-transcriptional regulation facilitates PD-L1 protein production and tumor immune suppression.
    Cancer Lett. 2026;649:218470.
    

    >> Share

    
    

    
    Clin Cancer Res

11. FOOTE MB, Harada G, Abdelfattah S, Urganci N, et al
    Molecular lineages of sporadic mismatch-repair deficient colorectal cancer.
    Clin Cancer Res. 2026 Apr 21. doi: 10.1158/1078-0432.CCR-26-0024.
    

    >> Share

    
    

    
    Dis Colon Rectum

12. THAM SZL, Yang E
    Colonic Stenting in Obstructed Colorectal Cancer as a Bridge to Surgery.
    Dis Colon Rectum. 2026 Apr 21. doi: 10.1097/DCR.0000000000004257.
    

    >> Share

    
    

    
    Gastroenterology

13. TERLOUW D, Suerink M, Buitelaar Y, van Leerdam ME, et al
    Prevalence and Consequences of APC Mosaicism in Patients With Colorectal Adenomas.
    Gastroenterology. 2026;170:932-941.
    

    >> Share

    
    
14. BOUCHIBA H, Aelvoet AS, van Kouwen MCA, Bastiaansen BAJ, et al
    Incidence of Cancer in Patients With Familial Adenomatous Polyposis in the Netherlands: A Nationwide Cohort Study.
    Gastroenterology. 2026;170:942-952.
    

    >> Share

    
    

    
    Int J Cancer

15. FOUNTZILAS C, Rosario S, Witkiewicz AK, Withers HG, et al
    TP53 mutation is associated with improved disease control in patients with advanced RAS wild-type colorectal adenocarcinoma treated with cetuximab and pembrolizumab.
    Int J Cancer. 2026;158:3300-3311.
    

    >> Share

    
    
16. MORKEN S, Langer SW, Hjortland GO, Sundlov A, et al
    Molecular-clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomas.
    Int J Cancer. 2026;158:3217-3231.
    

    >> Share

    
    

    
    J Clin Oncol

17. OBERSTEIN PE, Hecht JR, Raghav K, Pietrantonio F, et al
    Amivantamab Monotherapy in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study.
    J Clin Oncol. 2026 Apr 21:JCO2502187. doi: 10.1200/JCO-25-02187.
    

    >> Share

    
    

    
    Oncogene

18. LI C, Deng S, Zhuang M, Li T, et al
    MTPN drives noncanonical ERK hyperactivation in colorectal cancer and provides a promising therapeutic approach for precision medicine in CRC.
    Oncogene. 2026 Apr 20. doi: 10.1038/s41388-026-03795.
    

    >> Share

    
    
19. ZHENG Z, Ni Y, Wu M, Ding L, et al
    USP13 stabilizes SOCS1 to reverse alphaPD-1 resistance in MSI-H colorectal cancer.
    Oncogene. 2026 Apr 18. doi: 10.1038/s41388-026-03782.
    

    >> Share

    
    

    
    PLoS One

20. YANG J, Morhard R, Huth H, Karim B, et al
    Antitumoral immunity induced by gel ethanol ablation to treat unresectable colorectal cancer metastases in the liver.
    PLoS One. 2026;21:e0347625.
    

    >> Share

    
    
21. FERNANDEZ FIGUEROA EA, Falcon-Martinez JC, Garcia-Gordillo JA, Coquis-Navarrete U, et al
    Beyond individual markers: Prognostic value of the combined CEA/PNI score in metastatic colorectal cancer as a predictor of survival.
    PLoS One. 2026;21:e0346932.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share